This article is more than 5 years old. Information may no longer be current.

Study: PDT may not completely occlude CNV

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CLEVELAND — Verteporfin ocular photodynamic therapy does not appear to lead to permanent and complete occlusion of choroidal neovascularization, according to a study. Treatments that can permanently close CNV without incurring retinal damage are still needed, the authors said.

Peter Kaiser, MD, and colleagues here at Cole Eye Institute retrospectively reviewed eight eyes of eight patients who underwent submacular surgery for choroidal neovascularization (CNV) after having previously received verteporfin ocular photodynamic therapy (PDT). One patient had presumed histoplasmosis, three had age-related macular degeneration, two had pathologic myopia, one had punctate inner choroiditis, and one had idiopathic CNV.

Choroidal neovascular membranes were removed anywhere from 3 to 152 days after PDT. Areas of vascular occlusion at 3 days were not seen at later time points upon histopathologic and ultrastructural examination. All specimens had patent CNV; signs of vascular damage were seen in all but the 3-day specimen.

The study is published in the March issue of American Journal of Ophthalmology.